The CBD market is set to be one of the fastest growing sectors in 2018, edible CBD products are making CBD more accessible than ever and companies like Ubiquitech Software Corp. (OTCMKTS:UBQU) are on the forefront of this revolution.

(Source: Pixabay)

CBD products have begun to carve themselves an important niche in the alternative medicine market. In the wake of an opioid crisis that cost the American economy over $500 billion in 2015, medical professionals and their patients have been searching for an alternative. For a long time, the focus has been on medical marijuana but now studies are beginning to show that the hemp derivative cannabidiol (CBD) might be a viable alternative to traditional painkillers.

The CBD market exploded in 2017 and is set to continue growing at a remarkable pace over the next few years. Through its subsidiary HempLifeToday, Ubiquitech Software Corp. (OTCMKTS:UBQU) is beginning to position itself as one of the industry leaders.

A medical consensus is beginning around the benefits of CBD

While the number of studies into the potential benefits of CBD is limited, the early results are very compelling indeed. CBD has already been used for some time as a potential pain remedy, but it has also shown applications in treating mental illness and long-term joint or bone pains. CBD is useful because it allows patients to experience the benefits of medical marijuana without the accompanying high. This has allowed it to become a legal substance in many countries.

(Source: Pixabay)

The European Journal of Pain and the Journal of Experimental Medicine have both shown that CBD was an effective treatment for pain in animal trials. They also demonstrated that CBD does not have many of the more notable side effects associated with traditional opioid-based painkillers. The most notable finding was that the body does not seem to build up a resistance to CBD, meaning that there is no need to increase the dosage over time.

Athletes have also begun to use CBD to help them cope with the pains associated with high impact sports. The evidence that CBD is useful for managing muscle pains eventually led to the World Anti-Doping Agency to remove CBD from their list of prohibited substances in 2018. This is significant because it will help to legitimize the use of CBD as a part of a pain management routine. The ruling should also help to separate hemp derived CBD from its associations with marijuana.

Edible CBDs have proven popular because they make dosage easier

There are many different ways to administer CBD. Some people prefer to use a vaping pen to inhale it, others prefer to apply CBD topically through a muscle cream, and some simply ingest CBD oil using a dripper. Not everybody is comfortable using these methods and it can be difficult to dose correctly using a cream or oil dropper.

This has led to a number of users opting to use CBD edibles. These are usually in the form of sweets or gummies and are designed to make it easy to dose and ingest your CBD without changing your daily ritual. The market potential of CBD edibles is absolutely huge and they could help to significantly boost the popularity of CBD in general.

Earlier this year Ubiquitech Software Corp. took steps to enter into this lucrative market when they announced plans to add edible gummies to their cannazALL line of CBD products. HempLifeToday already offers a variety of different CBD products from tinctures to creams and gel-cap ingestibles. The addition of edibles to their product line will give the supplier a boost and should help produce a strong 2018 performance for the CBD supplier.

The CBD market still has plenty of room to grow. If they are able to keep bringing out innovative products, HempLifeToday and Ubiquitech Software Corp. are set to do very well.